en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6579.com › Wiki › Research History And Clinical Assessment — Quick Reference

Research History And Clinical Assessment — Quick Reference

By Editorial Desk · published 2026-02-05 · last reviewed 2026-03-11 · Wiki

合成肽 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.

Research History and Clinical Assessment

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Background, Structure, and Mechanism

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Thymosin-alpha-1 at a glance

PropertyValueNotes
First described1977Reported as a component of thymosin fraction 5
Sequence length28 amino acidsN-terminal residue is acetylated
Net charge at neutral pHNegativeReflects a high proportion of acidic residues
Principal studied usesChronic hepatitis B and vaccine adjuvantResearch uses outnumber approved indications
Regulatory statusApproved in a limited number of countriesNot approved in the United States or most of Europe

分子身份与天然来源

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

Related pages on this site

Molecular Background and Identity

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Background and Mechanism of Action

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Background from the literature

One of the confirmations of the end of an era of greater tolerance was the expulsion from the communist party of several prominent "Marxist revisionists" in the 1960s. In 1965, the Conference of Polish Bishops issued the Letter of Reconciliation of the Polish Bishops to the German Bishops, a gesture intended to heal bad mutual feelings left over from World War II. In 1966, the celebrations of the 1,000th anniversary of the Christianization of Poland led by Cardinal Stefan Wyszyński and other bishops turned into a huge demonstration of the power and popularity of the Catholic Church in Poland. The post-1956 liberalizing trend, in decline for a number of years, was reversed in March 1968, when student demonstrations were suppressed during the 1968 Polish political crisis. Motivated in part by the Prague Spring movement, the Polish opposition leaders, intellectuals, academics and students used a historical-patriotic Dziady theater spectacle series in Warsaw (and its termination forced by the authorities) as a springboard for protests, which soon spread to other centers of higher education and turned nationwide. The authorities responded with a major crackdown on opposition activity, including the firing of faculty and the dismissal of students at universities and other institutions of learning. At the center of the controversy was also the small number of Catholic deputies in the Sejm (the Znak Association members) who attempted to defend the students. In an official speech, Gomułka drew attention to the role of Jewish activists in the events taking place.

The Norma Oficial Mexicana (NOM) applies to all processes and activities related to the supply of agave, production, bottling, marketing, information, and business practices linked to the distilled alcoholic beverage known as tequila. Tequila must be produced using agave of the species Tequilana Weber Blue variety, grown in the federal states and municipalities indicated in the Declaration. Furthermore, the NOM establishes the technical specifications and legal requirements for the protection of the Appellation of Origin of "Tequila" in accordance with the current General Declaration of Protection of the Appellation of Origin of "Tequila", the Law, the Industrial Property Law, the Federal Consumer Protection Law and other related legal provisions. All authentic, regulated tequilas will have a NOM identifier on the bottle. The important laws since 1990 were NOM-006-SCFI-1993, the later updates NOM-006-SCFI-1994 and NOM-006-SCFI-2005 and the most recent revision published on December 13, 2012, NOM-006-SCFI-2012. The number after NOM is the distillery number, assigned by the government. NOM does not indicate the location of the distillery, merely the parent company or, in the case where a company leases space in a plant, the physical plant where the tequila was manufactured.

Plasma levels of progesterone are similar after vaginal and rectal administration in spite of the different routes of administration, and rectal administration is an alternative to vaginal progesterone in conditions of vaginal infection, cystitis, recent childbirth, or when barrier contraception methods are used. Intramuscular injection of progesterone may achieve much higher levels of progesterone than normal luteal phase concentrations and levels achieved with other routes.

Sources: en.wikipedia.org

Reference notes

=== Strain Release === Strain-release amination (2016) Stereospecific strain-release cyclopentylation of amines, alcohols, thiols, carboxylic acids, and other heteroatoms (2017) Enantiocontrolled Azetidine Library Synthesis via Strain Release Functionalization of 1-Azabicyclobutanes (2024)

=== Thermal-induced phase separation === Thermal-induced phase separation separates a homogenous polymer solution into a multi-phase system via thermodynamic changes. The procedure involves five steps: polymer dissolution, liquid-liquid or liquid-solid phase separation, polymer gelation, extraction of solvent from the gel with water, and freezing and freeze-drying under vacuum. Thermal-induced phase separation method is widely used to generate scaffolds for tissue regeneration. The homogenous polymer solution in the first step is thermodynamically unstable and tends to separate into polymer-rich and polymer-lean phases under appropriate temperature. Eventually after solvent removal, the polymer-rich phase solidifies to form the matrix and the polymer-lean phase develops into pores. Next, two types of phase separation can be carried out on the polymer solution depending on the desired pattern. Liquid-liquid separation is usually used to form bicontinuous phase structures while solid-liquid phase separation is used to form crystal structures. The gelation step plays a crucial role in controlling the porous morphology of the nanofibrous matrices. Gelation is influenced by temperature, polymer concentration, and solvent properties. Temperature regulates the structure of the fiber network: low gelation temperature results in formation of nanoscale fiber networks while high gelation temperature leads to the formation of a platelet-like structure.

== Properties == The S−S bond dissociation energy is 305±21 kJ/mol, about 80 kJ/mol stronger than the S−S bond in diphenyldisulfide. At temperatures above 150 °C (302 °F), S2F10 decomposes slowly (disproportionation) into SF6 and sulfur tetrafluoride (SF4):

Sources: en.wikipedia.org

Reference notes

=== Rabbit Test === Early endotoxin detection was accomplished by injecting rabbits with the sample and observing the response in their body temperature. Rabbits have similar endotoxin tolerance to humans, and were thus an ideal choice. However, this method was costly, time consuming, and prompted protests from animals rights advocates. But perhaps the biggest drawback of this test was its inability to quantify the endotoxin level.

It was traditionally assumed that the first reptiles retained an anapsid skull inherited from their ancestors. This type of skull has a skull roof with only holes for the nostrils, eyes and a pineal eye. The discoveries of synapsid-like openings (see below) in the skull roof of the skulls of several members of Parareptilia (the group containing most of the amniotes traditionally referred to as "anapsids"), including lanthanosuchoids, millerettids, bolosaurids, some nycteroleterids, some procolophonoids and at least some mesosaurs made it more ambiguous and it is currently uncertain whether the ancestral amniote had an anapsid-like or synapsid-like skull. These animals are traditionally referred to as "anapsids", and form a paraphyletic basic stock from which other groups evolved. Very shortly after the first amniotes appeared, a lineage called Synapsida split off; this group was characterized by a temporal opening in the skull behind each eye giving room for the jaw muscle to move. These are the "mammal-like amniotes", or stem-mammals, that later gave rise to the true mammals. Soon after, another group evolved a similar trait, this time with a double opening behind each eye, earning them the name Diapsida ("two arches"). The function of the holes in these groups was to lighten the skull and give room for the jaw muscles to move, allowing for a more powerful bite.

Works by or about Frederick Banting at the Internet Archive Banting House National Historic Site (Archived January 17, 2021, at the Wayback Machine) Frederick Banting on Nobelprize.org including the Nobel Lecture on September 15, 1925, "Diabetes and Insulin" Ontario Plaques – The Discovery of Insulin (Archived December 22, 2015, at the Wayback Machine) CBC Digital Archives – Chasing a Cure for Diabetes Simcoe County Archives – "Sir Frederick Banting" Famous Canadian Physicians: Sir Frederick Banting at Library and Archives Canada World Diabetes Day on Banting's Birthday, November 14 1928 A.Y. Jackson and Frederick Banting – NWT Historical Timeline, Prince of Wales Northern Heritage Centre Frederick Banting Papers, Thomas Fisher Rare Book Library Archived March 14, 2012, at the Wayback Machine The Discovery and Early Development of Insulin Digital Collection, Toronto

== History == The first IUD was developed in 1909 by the German physician Richard Richter of Waldenburg. Unlike modern intrauterine devices, early interuterine (from Latin inter-, meaning "between", as opposed to intra-) devices crossed both the vagina and the uterus, causing a high rate of pelvic inflammatory disease. Ernst Gräfenberg, another German physician (after whom the G-spot is named), created the first Ring IUD, Gräfenberg's ring, made of silver filaments. His work was suppressed during the Nazi regime, when contraception was considered a threat to Aryan women. In 1935, Gräfenberg, who was Jewish, was in jail in Berlin and Margaret Sanger paid a ransom to have him released. He moved to the United States and opened a private practice in New York, New York. His colleagues H. Hall and M. Stone took up his work after his death and created the stainless steel Hall-Stone Ring. Dr. Jack Lippes helped begin the increase of IUD use in the United States in the late 1950s. In this time, thermoplastics, which can bend for insertion and retain their original shape, became the material used for first-generation IUDs. Lippes also devised the addition of the nylon string to facilitate IUD removal. Lippes and his friend Paul Bronnenkant, a plastics developer, crafted the first Lippes Loop in Bronnenkant's kitchen, heating and molding the plastic on cookie sheets in the oven. His trapezoid-shaped Lippes Loop IUD became one of the most popular first-generation IUDs. In the following years, many different-shaped plastic IUDs were invented and marketed.

Sources: en.wikipedia.org

Frequently asked questions

Why are clinical results inconsistent?

Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.

In which countries is thymosin alpha 1 approved?

Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.

How is the peptide characterized in review articles?

Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.

What is thymosin alpha-1 derived from?

It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.

Network